ABSTRACT
Viskaldix, a combination of Pindolol (Visken)--10 mg with Clopamide--5 mg, was administered to 15 patients with arterial hypertension. The follow up of the patients was according to a previous plan, the preparation administered according, to a schedule. In the determination of the stage of the disease, consideration was mainly given to the values of the diastolic pressure, measured in a lying position. The patients examined were of the following age: to 40--I patient; to 50-7 patients; to 60--7 patients. Seven patients were at the stage I, 4 patients--stage OII and 4 patients--stage III. Reduction of systolic and diastolic pressure with more than 1.33 kPa (10 mm Hg column) both in a lying and standing position were recorded in 2/3 of the patients with the treatment carried out. The effect on the blood pressure, was noticed to develop in 1/3 of the patients with the administration of 2 tablets daily. The blood pressure of only one patient failed to respond to the treatment.
Subject(s)
Antihypertensive Agents , Clopamide/administration & dosage , Clopamide/therapeutic use , Diuretics/administration & dosage , Pindolol/administration & dosage , Pindolol/therapeutic use , Adult , Antihypertensive Agents/administration & dosage , Antihypertensive Agents/adverse effects , Clopamide/adverse effects , Drug Combinations/administration & dosage , Drug Combinations/adverse effects , Drug Combinations/therapeutic use , Humans , Hypokalemia/chemically induced , Middle Aged , Pindolol/adverse effectsABSTRACT
A case with symptomatic erythrocytosis in a female patient with ductus Botalli persistens is described, diagnosed and treated as erythremia vera. The heart disease advanced with no manifestations, with no complaints until the age of 30, whereon it was manifested with certain complaints and objective findings. The inadequate and difficult assessment of some of the clinical, hematological and other data as X-ray of the heart and ECG, contributed to the improper diagnosis. The patient died at the age of 54.
